A small cohort of patients (n= 10) in a hospital in Italy were given 300 mg Canakinumab (administered subcutaneously) along with 200 mg of hydroxychloroquine (twice daily) and lopinavir-ritonavir (400 mg twice daily of lopinavir and 100 mg twice daily of ritonavir). All patients had bilateral pneumonia and hyperinflammation. Patients experienced no injection site reactions and a reduction in serum C-reactive protein at day 1 and 3. After 45 days, all patients were discharged with physical imitations. A comparison was made retrospectively with a group of 10 patients from a few months prior; however, this was an indirect comparison.